Pasadena, California 91107

  • Ocular Hypertension

Purpose:

This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.


Criteria:

Inclusion Criteria: • Diagnosis of either Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment Exclusion Criteria: - Concurrent or anticipated enrollment in another investigational drug or device study or participation in such a study within 2 months prior to enrolling in this study - Previous administration with Bimatoprost SR in the study eye


NCT ID:

NCT03850782


Primary Contact:

Study Director
Saumya Nagar
Allergan

Clinical Trials Registry Team
Phone: 1-877-277-8566
Email: IR-CTRegistration@allergan.com


Backup Contact:

N/A


Location Contact:

Pasadena, California 91107
United States

Study Coordinator
Phone: 626-335-0535

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 28, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.